

# Victor Maximilian Schuettfort

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800461/publications.pdf>

Version: 2024-02-01

65  
papers

715  
citations

687363

13  
h-index

752698

20  
g-index

65  
all docs

65  
docs citations

65  
times ranked

627  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. European Urology Focus, 2022, 8, 447-456.	3.1	3
2	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	2.5	16
3	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	3.1	10
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	4.2	6
5	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	2.5	2
6	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU International, 2022, 129, 423-433.	2.5	37
7	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology Focus, 2022, 8, 1072-1089.	3.1	14
8	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	2.7	6
9	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	1.9	20
10	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	2.2	4
11	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 106.e11-106.e19.	1.6	14
12	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	1.9	3
13	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	2.5	2
14	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	2.5	8
15	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	3.1	3
16	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2022, 56, 85-93.	1.0	3
17	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 71-80.	1.5	2
18	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6
20	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	3.1	10
21	Prognostic impact of insulin-like growth factor-1 and its binding proteins, insulin-like growth factor-1 binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	1.0	3
22	The placebo and nocebo effects in functional urology. <i>Nature Reviews Urology</i> , 2022, 19, 171-189.	3.8	5
23	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
24	Risk factors for concomitant positive midstream urine culture in patients presenting with symptomatic ureterolithiasis. <i>Urolithiasis</i> , 2022, , 1.	2.0	2
25	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
26	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	2.2	20
27	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	1.6	8
28	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1149-1157.	1.3	4
29	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	2.0	5
30	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	2.2	18
31	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
32	Prognostic role of the systemic immune-inflammatory index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	4.2	21
33	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	1.4	5
34	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 180-190.	1.6	10
35	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 755-765.	5.4	100
36	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Journal of Urology</i> , 2021, 205, 1018-1030.	0.4	27

#	ARTICLE	IF	CITATIONS
37	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 4085-4099.	2.2	9
38	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. <i>BJU International</i> , 2021, 128, 280-289.	2.5	17
39	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. <i>Prostate</i> , 2021, 81, 765-771.	2.3	4
40	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. <i>Current Opinion in Urology</i> , 2021, 31, 324-331.	1.8	5
41	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 3771-3779.	2.2	10
42	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	1.0	7
43	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 9179-9187.	1.5	3
44	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1587-1599.	2.2	16
45	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
46	Impact of systemic Immune-inflammatory Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	1.6	14
47	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	2.2	18
48	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	2.8	24
49	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773.	1.6	14
50	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 917-929.	2.0	1
51	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479.	1.6	7
52	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	7.7	13
53	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	2.2	3
54	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 610-615.	2.5	6
56	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	8
57	Pathomics in urology. <i>Current Opinion in Urology</i> , 2020, 30, 823-831.	1.8	10
58	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	2.2	6
59	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	2.2	45
60	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2020, 39, 1961-1968.	2.2	10
61	Learning benefits of live surgery and semi-live surgery in urologyâ€”informing the debate with results from the International Meeting of Reconstructive Urology (IMORU) VIII. <i>World Journal of Urology</i> , 2020, 39, 2801-2807.	2.2	3
62	Management of de-novo urothelial carcinoma in transplanted patients. <i>Current Opinion in Urology</i> , 2020, 30, 467-474.	1.8	7
63	Live surgery in reconstructive urology: evaluation of the surgical outcome and educational benefit of the international meeting on reconstructive urology (IMORU). <i>World Journal of Urology</i> , 2019, 37, 2533-2539.	2.2	2
64	The T-plasty as therapy for recurrent bladder neck stenosis: success rate, functional outcome, and patient satisfaction. <i>World Journal of Urology</i> , 2017, 35, 1907-1911.	2.2	16
65	Transperineal reanastomosis for treatment of highly recurrent anastomotic strictures after radical retropubic prostatectomy: extended follow-up. <i>World Journal of Urology</i> , 2017, 35, 1885-1890.	2.2	29